Expert Interview
Discussing the update of NVL-655 in ALK NSCLC from ESMO
Ticker(s): NUVLInstitution: Mount Sinai
- Assistant professor of Medicine, Hematology and Medical Oncology, and a board certified medical oncologist who specializes in the treatment of lung cancer and other thoracic malignancies.
- Translational researcher focused on studying predictive biomarkers and developing novel targeted and immunotherapy trials aimed at improving treatment outcomes in lung cancer patients.
- PI of several lung cancer trials, including investigator initiated trials based on proteogenomic analyses used to identify novel therapeutic targets.
How many patients with ALK-positive non-small cell lung cancer do you currently manage, and what are the treatment options you employ in the third line and beyond? How does the efficacy of NVL-655 compare to these options?
How frequently do you observe compound ALK mutations in your clinical practice, and what are your perspectives on the efficacy of NVL-655 in treating these mutations, particularly after lorlatinib?
What are your observations on the development of the G1202R mutation, and how does NVL-655’s potential efficacy in the second line compare to existing options like lorlatinib for patients with this mutation?
What are your takeaways regarding NVL-655’s duration of response and CNS activity in heavily pretreated patients, especially in those with CNS progression while on lorlatinib? What are the expectations for intracranial efficacy in third-line treatments?
How does NVL-655's safety profile compare to other approved TKIs like lorlatinib? What expectations do you have for NVL-655 in second and first-line settings, particularly regarding efficacy, safety profile trade-offs, and trial design comparisons with other ALK-TKIs like alectinib?
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
